Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - cyclophosphamide monohydrate 2138mg equivalent to cyclophosphamide anhydrous 2000 mg;   - powder for injection - 2000 mg - active: cyclophosphamide monohydrate 2138mg equivalent to cyclophosphamide anhydrous 2000 mg   - the proper use of cyclophosphamide requires accurate diagnosis, careful assessment of the anatomic extent of the disease, knowledge of the type and effects of any previous therapy, and continued evaluation of the patient's general and haematologic status. it is essential that adequate clinical and laboratory facilities be available for proper monitoring of patients during treatment with cyclophosphamide. the clinical course of the disease should be recorded in objective terms before treatment is begun and thereafter at regular intervals. careful management of patients receiving cyclophosphamide will help achieve maximum benefit with minimum risk. antineoplastic properties: patients with neoplasms that might preferably be treated by surgical and/or irradiation procedures should ordinarily not be treated by chemotherapy alone.

Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - cyclophosphamide monohydrate - oral tablet - 50mg

Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - cyclophosphamide monohydrate - oral tablet - 50mg

Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - cyclophosphamide monohydrate - oral tablet - 50mg

Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

cst pharma ltd - cyclophosphamide monohydrate - oral tablet - 50mg

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

baxter healthcare corporation - cyclophosphamide (unii: 8n3dw7272p) (cyclophosphamide anhydrous - unii:6uxw23996m) - cyclophosphamide tablets is indicated for the treatment of: cyclophosphamide, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs. cyclophosphamide tablets is indicated for the treatment of biopsy proven minimal change nephrotic syndrome in pediatric patients who failed to adequately respond to or are unable to tolerate adrenocorticosteroid therapy. limitations of use: the safety and effectiveness of cyclophosphamide tablets for the treatment of nephrotic syndrome in adults or other renal disease has not been established. cyclophosphamide tablets are contraindicated in patients with: risk summary based on its mechanism of action and published reports of effects in pregnant patients or animals, cyclophosphamide tablets can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1) and nonclinical toxicology (13.1)]. exposure to cyclophosphamide during pregnancy may cause fetal malformations

Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

sandoz ltd - cyclophosphamide monohydrate - powder for solution for injection - 2gram

Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

sandoz ltd - cyclophosphamide monohydrate - powder for solution for injection - 1gram

Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

sandoz ltd - cyclophosphamide monohydrate - powder for solution for injection - 500mg

Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

baxter healthcare ltd - cyclophosphamide monohydrate - powder for solution for injection - 500mg